Recently, a phase I clinical trial demonstrated that PF‐07248144, a dual KAT6A and KAT6B inhibitor, in combination with endocrine therapy (ET), exhibited promising antitumor efficacy and manageable safety profiles in patients with ER+/human epidermal growth factor receptor 2‐negative (HER2−) (ER+/HER2−) advanced breast cancer (ABC) following standard treatment with cyclin‐dependent kinases 4/6 inhibitor (CDK4/6i) [37]. This evidence concerns the gene KAT6B and breast carcinoma.